Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details) - Vaxcyte, Inc. $ in Thousands |
3 Months Ended |
|---|---|
|
Mar. 31, 2024
USD ($)
| |
| Deferred Royalty Obligation [Line Items] | |
| Liability related to sale of future Vaxcyte royalties - beginning balance | $ 149,114 |
| Non-cash interest expense associated with the sale of future Vaxcyte royalties | 7,184 |
| Amortization of issuance costs | 167 |
| Liability related to the sale of future Vaxcyte royalties - ending balance | $ 156,465 |